News

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the proposed Outbound Investment Security Program (OISP) rule:"The Administration is correct that…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…

BIO filed an amicus brief in the U.S. Court of Appeals for the District of Columbia Circuit, seeking the reversal of a lower court decision that found plaintiff Vertex Pharmaceuticals’ patient assistance program in violation of the Anti-Kickback…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …